Delivery Order SPE2DB20D3303-SPE2DB25FA3XB
- Not listed
- The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tagrisso 80 mg tablets (30-unit package). This contract represents a competitive, firm fixed-price procurement with no set-aside designation and a completion date of September 10, 2025. The award is executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages) with a ceiling value of $21.3K. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is scheduled for completion by October 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $21,325.14 under a firm fixed-price contract. This non-set-aside award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $10,662.57. The order is scheduled for completion by September 2, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tagrisso 80 mg tablets (30-count units) on August 15, 2025, with completion targeted for September 8, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,662.57 on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a $58,164.68 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this order supports the...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, consistent...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3XBDelivery Order
The Defense Logistics Agency awarded a $21,325.14 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price contract with an ultimate completion date of October 9, 2025. The award represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be fulfilled from the contractor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply role supporting federal military and healthcare systems through the DLA's global pharmaceutical support vehicle. Tagrisso is a targeted cancer therapy used primarily in oncology treatment regimens. The transaction exemplifies the Defense Logistics Agency's reliance on AmerisourceBergen as a critical pharmaceutical distributor for the Defense Health Agency and other military healthcare programs, enabling efficient procurement of specialized brand-name medications across multiple therapeutic domains to support DOD medical operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 9/18/25 |